Opus Genetics, Inc.
IRD
$3.61
-$0.11-2.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 755.00K | 2.16M | 3.87M | 3.08M | 2.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 755.00K | 2.16M | 3.87M | 3.08M | 2.88M |
| Cost of Revenue | 11.11M | 10.48M | 10.43M | 6.41M | 5.92M |
| Gross Profit | -10.35M | -8.32M | -6.56M | -3.33M | -3.04M |
| SG&A Expenses | 6.13M | 6.04M | 4.89M | 4.98M | 5.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.24M | 16.52M | 15.32M | 11.39M | 11.79M |
| Operating Income | -16.48M | -14.36M | -11.45M | -8.31M | -8.91M |
| Income Before Tax | -8.10M | -65.54M | -16.52M | -17.45M | -7.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.10M | -65.54M | -16.52M | -17.45M | -7.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.10M | -65.54M | -16.52M | -17.45M | -7.42M |
| EBIT | -16.48M | -14.36M | -11.45M | -8.31M | -8.91M |
| EBITDA | -16.47M | -14.35M | -11.44M | -8.30M | -8.89M |
| EPS Basic | -0.08 | -0.75 | -0.21 | -0.25 | -0.12 |
| Normalized Basic EPS | -0.05 | -0.47 | -0.13 | -0.15 | -0.07 |
| EPS Diluted | -0.14 | -0.75 | -0.21 | -0.25 | -0.12 |
| Normalized Diluted EPS | -0.05 | -0.47 | -0.13 | -0.15 | -0.07 |
| Average Basic Shares Outstanding | 95.48M | 86.89M | 80.59M | 70.64M | 63.38M |
| Average Diluted Shares Outstanding | 111.38M | 86.89M | 80.59M | 70.64M | 63.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |